Association between sleep disorders and injury: a nationwide population-based retrospective cohort study

Lin, Chia-Ling; Chung, Chi‐Hsiang; Tsai, Yu‐Hsia; Chien, Wu-Chien

doi:10.1136/injuryprev-2015-041844

Cited by 9 publications

(5 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, OSA among the nonobese population is treated as less adherent and ignores related treatment (Gülbay et al, 2019). Another concerning phenomenon our study found was that OSA patients aged 20-44 years had a 93% higher risk for injury than controls, inconsistent with a previous study that indicated that OSA increased with increasing age, subjects had OSA and increased the risk of injury (Lin et al, 2016). Hence, we suggest that future research should focus on a young OSA population and different types of injury.…”

Section: Individuals With Injury 2925 Individuals With Injurycontrasting

confidence: 71%

“…The injury event was defined by the ICD-9-CM codes (N-Code 800-999) during the period between 2000 and 2013, we further classified the injuries as unintentional (traffic, falls, and poisoning) and intentional (suicide), based on definition of injuries type by prior research (Centers for Disease Control & Prevention, 2012;Lin et al, 2016).…”

Section: Discussionmentioning

confidence: 99%

“…Previous studies have indicated that patients with sleep disorders have a higher risk of injury (Lin et al, 2016;Rajaratnam et al, 2011). In particular, numerous studies examined the correlation between OSA and motor vehicle accidents (MVAs) and occupational injuries (OIs), indicating that individuals with OSA have a 17% higher risk of MVAs and two times the risk of OIs (Allen et al, 2020;Carls et al, 2020;Lin et al, 2020;Purtle et al, 2020).…”

mentioning

confidence: 99%

See 2 more Smart Citations

Obstructive sleep apnea and injury events in Taiwanese adults: A retrospective cohort study

Lin

et al. 2021

J of Nursing Scholarship

View full text Add to dashboard Cite

Obstructive sleep apnea (OSA) is a pervasive sleep disorder. An epidemiological study reported that an estimated 425 million adults aged 30-69 years have moderate to severe OSA globally with negative health impacts (Benjafield et al., 2019). The prevalence of OSA in the adult population is 3%-17%; OSA increases with age (Punjabi, 2008;Senaratna et al., 2017), with a higher prevalence in men and those with a high body mass index (Senaratna et al., 2017). OSA has been shown to be closely associated with chronic diseases, such as hypertension (Hou et al., 2018), type 2 diabetes (Wang et al., 2013) and cardiovascular disease (Bradley & Floras, 2009).

show abstract

Section: Individuals With Injury 2925 Individuals With Injurycontrasting

confidence: 71%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Obstructive sleep apnea and injury events in Taiwanese adults: A retrospective cohort study

Lin

et al. 2021

J of Nursing Scholarship

View full text Add to dashboard Cite

show abstract

“…In DSM-5, insomnia disorder is defined as the complaint of poor sleep occurring at least 3 nights per week for at least 3 months with associated significant daytime effects [ 4 ]. Insomnia has been associated with an increased risk of various medical [ 5 – 7 ] and psychiatric disorders [ 8 , 9 ] and injuries [ 10 ]. Sleep disorders in patients with medical conditions are assumed to negatively affect prognosis [ 11 ].…”

Section: Introductionmentioning

confidence: 99%

TIMELAPSE study—efficacy of low-dose amitriptyline versus cognitive behavioral therapy for chronic insomnia in patients with medical comorbidity: study protocol of a randomized controlled multicenter non-inferiority trial

Rauwerda

Knoop

Pot

et al. 2021

Trials

View full text Add to dashboard Cite

Background Insomnia is common in people with long-term medical conditions and is related to increased mortality and morbidity. Cognitive behavioral therapy for insomnia (CBT-I) is first choice treatment and effective for people with insomnia and comorbid long-term medical conditions. However, CBT-I has some limitations as it might not always be available or appeal to patients with medical conditions. Furthermore, a small proportion of patients do not respond to CBT-I. Preliminary evidence and clinical experience suggest that low-dose amitriptyline (AM) might be an effective alternative to treat insomnia in patients with medical comorbidity. In this randomized controlled trial, we will determine whether AM is non-inferior to the first choice treatment for insomnia, CBT-I. Methods/design This study will test if treatment with low-dose amitriptyline for insomnia in patients with medical comorbidity is non-inferior to CBT-I in a multicenter randomized controlled non-inferiority trial. Participants will be 190 adults with a long-term medical condition and insomnia. Participants will be randomly allocated to one of two intervention arms: 12 weeks AM (starting with 10 mg per day, and if ineffective at 3 weeks, doubling this dose) or 12 weeks of CBT-I consisting of 6 weekly sessions and a follow-up session 6 weeks later. The primary outcome is subjective insomnia severity, measured with the Insomnia Severity Index (ISI). The primary endpoint is at 12 weeks. Secondary outcomes include sleep quality (e.g., sleep efficiency), questionnaires on daytime functioning (physical functioning and impairment of functioning), and symptoms (e.g., fatigue, pain, anxiety) at 12 weeks and 12 months post treatment and relapse of insomnia until 12 months after treatment. Discussion Irrespective of the outcome, this study will be a much-needed contribution to evidence based clinical guidelines on the treatment of insomnia in patients with medical comorbidity. Trial registration Dutch Trial Register NTR NL7971. Registered on 18 August 2019

show abstract

“…In DSM-5, insomnia disorder is de ned as the complaint of poor sleep occurring at least 3 nights per week for at least 3 months with associated signi cant daytime effects (4). Insomnia has been associated with an increased risk of various medical (5-7) and psychiatric disorders (8, 9) and injuries (10). Sleep disorders in patients with medical conditions are assumed to negatively affect prognosis (11).…”

Section: Introductionmentioning

confidence: 99%

TIMELAPSE Study Efficacy of Low Dose Amitriptyline Versus Cognitive Behavioral Therapy For Chronic Insomnia In Patients With Medical Comorbidity: Study Protocol of A Randomized Controlled Multicenter Non Inferiority Trial.

Rauwerda

Knoop

Pot

et al. 2021

Preprint

View full text Add to dashboard Cite

Background Insomnia is common in people with long-term medical conditions and is related to increased mortality and morbidity. Cognitive behavioral therapy for insomnia (CBT-I) is first choice treatment and effective for people with insomnia and comorbid long-term medical conditions. However, CBT-I has some limitations as it might not always be available or appeal to patients with medical conditions. Furthermore, a small proportion of patients do not respond to CBT-I. Preliminary evidence and clinical experience suggest that low dose amitriptyline (AM) might be an effective alternative to treat insomnia in patients with medical comorbidity. In this randomized controlled trial we will determine whether AM is non-inferior to the first choice treatment for insomnia, CBT-I.Methods / design This study will test if treatment with low dose amitriptyline for insomnia in patients with medical comorbidity is non-inferior to CBT-I in a multicenter randomized controlled non-inferiority trial. Participants will be 190 adults with a long-term medical condition and insomnia. Participants will be randomly allocated to one of two intervention arms: 12 weeks AM (starting with 10 mg per day, and if ineffective at 3 weeks, doubling this dose) or 12 weeks of CBT-I consisting of 6 weekly sessions and a follow up session 6 weeks later. The primary outcome is subjective insomnia severity, measured with the Insomnia Severity Index (ISI). The primary endpoint is at 12 weeks. Secondary outcomes include sleep quality (e.g. sleep efficiency), questionnaires on daytime functioning (physical functioning and impairment of functioning) and symptoms (e.g. fatigue, pain, anxiety) at 12 weeks and 12 months post treatment and relapse of insomnia until 12 months after treatment. Discussion Irrespective of the outcome, this study will be a much-needed contribution to evidence based clinical guidelines on the treatment of insomnia in patients with medical comorbidity. Trail registration Dutch Trial Register, NTR NL7971, 18 August 2019

show abstract

Association between sleep disorders and injury: a nationwide population-based retrospective cohort study

Abstract: Comparing to patients with non-sleep disorders, patients with sleep disorders had a higher risk of injury and the risk was particularly pronounced in those who had insomnia.

Cited by 9 publications

References 25 publications

Obstructive sleep apnea and injury events in Taiwanese adults: A retrospective cohort study

Obstructive sleep apnea and injury events in Taiwanese adults: A retrospective cohort study

TIMELAPSE study—efficacy of low-dose amitriptyline versus cognitive behavioral therapy for chronic insomnia in patients with medical comorbidity: study protocol of a randomized controlled multicenter non-inferiority trial

TIMELAPSE Study Efficacy of Low Dose Amitriptyline Versus Cognitive Behavioral Therapy For Chronic Insomnia In Patients With Medical Comorbidity: Study Protocol of A Randomized Controlled Multicenter Non Inferiority Trial.

Contact Info

Product

Resources

About